Literature DB >> 12379776

Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer.

Sabine Glöckner1, Hilke Buurman, Wolfram Kleeberger, Ulrich Lehmann, Hans Kreipe.   

Abstract

Intratumoral heterogeneity mirrors subclonal diversity and might affect treatment response. To investigate molecular heterogeneity of primary breast cancer specimens, we determined the amplification status of growth regulatory genes (c-erbB2, topoisomerase IIalpha, c-myc, and cyclinD1) in macroscopically and microscopically separate areas of individual tumors (n = 21). Using laser-assisted microdissection and quantitative PCR, we found marked intratumoral heterogeneity with different patterns for each gene. Molecular heterogeneity in amplification pattern could be demonstrated between both macroscopically (0.5 to several centimeters) and microscopically (10 to several hundred micrometers) distant tumor areas. C-erbB2 amplification proved to be the most stable amplification in individual tumors, with heterogeneity occurring in only 36% of amplified cases. By contrast, amplification of c-myc and cyclinD1 revealed varying patterns in the vast majority of amplified cases (100% and 83%). The constancy of c-erbB2 amplification underlines its presumed importance in breast cancer biology. We conclude that the molecular heterogeneity of breast cancer as evidenced in this study requires thorough and representative sampling of different tumor areas when the biologic significance of somatic mutations is considered. Patterns of heterogeneity can be used to trace the clonal evolution within different compartments of an individual tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379776     DOI: 10.1097/01.lab.0000032371.16521.40

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  [Intratumoral heterogeneity of HER2 status in breast carcinoma].

Authors:  C Ohlschlegel; K Zahel; D Kradolfer; M Hell; W Jochum
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).

Authors:  Hratch Arbach; Viktor Viglasky; Florence Lefeu; Jean-Marc Guinebretière; Vanessa Ramirez; Nadège Bride; Nadia Boualaga; Thomas Bauchet; Jean-Philippe Peyrat; Marie-Christine Mathieu; Samia Mourah; Marie-Pierre Podgorniak; Jean-Marie Seignerin; Kenzo Takada; Irène Joab
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 4.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

5.  Evaluation of intratumoral HER-2 heterogeneity by fluorescence in situ hybridization in invasive breast cancer: a single institution study.

Authors:  Sarah Lee; Woohee Jung; Soon-Won Hong; Ja Seung Koo
Journal:  J Korean Med Sci       Date:  2011-07-27       Impact factor: 2.153

6.  Differential expression of cyclin D1 in the human hair follicle.

Authors:  Xiaowei Xu; Stephen Lyle; Yaping Liu; Benjamin Solky; George Cotsarelis
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

7.  The Clinical Importance of the Heterogeneity of HER2 neu.

Authors:  Enrique Davila; Kip Amazon
Journal:  Case Rep Oncol       Date:  2010-07-24

Review 8.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

Review 9.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

Review 10.  Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Authors:  Sanjay Srivatsan; Jaina M Patel; Erica N Bozeman; Imade E Imasuen; Sara He; Danielle Daniels; Periasamy Selvaraj
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.